Evidence map›Paper›PMID 37514072›Full record

ArticlePharmaceutics2023

Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics.

Md Musfizur Hassan, Bilquis Romana, Guangzhao Mao, Naresh Kumar, Fabio Sonvico, Pall Thordarson, Paul Joyce, Kristen E Bremmell, Timothy J Barnes, Clive A Prestidge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Md Musfizur HassanSchool of Chemistry, The Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Bilquis RomanaSchool of Chemistry, The Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Guangzhao MaoSchool of Chemical Engineering, The University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-9308-3922
Naresh KumarSchool of Chemistry, The Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Fabio SonvicoDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID 0000-0001-7372-1456
Pall ThordarsonSchool of Chemistry, The Australian Centre for Nanomedicine, The University of New South Wales, Sydney, NSW 2052, Australia.
Paul JoyceClinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0003-3619-7901
Kristen E BremmellClinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-7633-0562
Timothy J BarnesClinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-7367-3925
Clive A PrestidgeClinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-5401-7535
University of South Australia · AUUNSW Sydney · AUUniversity of Parma · IT

Funding

National Health and Medical Research Council APP1026382
6 · The paper itself

Abstract

Paclitaxel (PTX) and 5-fluorouracil (5-FU) are clinically relevant chemotherapeutics, but both suffer a range of biopharmaceutical challenges (e.g., either low solubility or permeability and limited controlled release from nanocarriers), which reduces their effectiveness in new medicines. Anticancer drugs have several major limitations, which include non-specificity, wide biological distribution, a short half-life, and systemic toxicity. Here, we investigate the potential of liposome-micelle-hybrid (LMH) carriers (i.e., drug-loaded micelles encapsulated within drug-loaded liposomes) to enhance the co-formulation and delivery of PTX and 5-FU, facilitating new delivery opportunities with enhanced chemotherapeutic performance. We focus on the combination of liposomes and micelles for co-delivery of PTX and 5_FU to investigate increased drug loading, improved solubility, and transport/permeability to enhance chemotherapeutic potential. Furthermore, combination chemotherapy (i.e., containing two or more drugs in a single formulation) may offer improved pharmacological performance. Compared with individual liposome and micelle formulations, the optimized PTX-5FU-LMH carriers demonstrated increased drug loading and solubility, temperature-sensitive release, enhanced permeability in a Caco-2 cell monolayer model, and cancer cell eradication. LMH has significant potential for cancer drug delivery and as a next-generation chemotherapeutic.

Indexed as

5-fluorouracilcancer cell uptakeliposome-micelle hybridliposomesmicellespaclitaxel

Identifiers

PMID37514072
PMCPMC10385268
OpenAlexW4383227091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.